Bank of Montreal
PRVL

Bank of Montreal’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Bank of Montreal’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,183
Closed -$50K – 5507
2020
Q4 		$50K Buy
2,183
+1,523
+231% +$19.3K ﹤0.01% 3945
2020
Q3 		$7K Sell
660
-477
-42% -$6.4K ﹤0.01% 4322
2020
Q2 		$18K Buy
+1,137
New +$17.5K ﹤0.01% 3907
2020
Q1 		– Sell
-936
Closed -$15K – 5018
2019
Q4 		$15K Buy
+936
New +$11.9K ﹤0.01% 4457

Bank of Montreal's PRVL Position: Q1 2021 in Review

Bank of Montreal sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 2,183 shares — an estimated $50K sold.

Bank of Montreal first reported a position in PRVL in Q4 2019 and held it in 4 quarters. The position peaked at $50K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Bank of Montreal reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Bank of Montreal sold 2,183 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $50K.
  • Bank of Montreal first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Bank of Montreal's Prevail Therapeutics Inc. Common Stock position peaked at $50K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Bank of Montreal's 13F filing for Q1 2021, filed 13 May 2021.